NINGXIA ZHONGKE BIOTECHNOLOGY CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.49 CNY | -5.10% |
|
-12.87% | -55.92% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,335 | 2,651 | 5,020 | 9,198 | 4,630 | 2,315 |
| Enterprise Value (EV) 1 | 3,711 | 3,586 | 6,330 | 10,597 | 6,008 | 3,276 |
| P/E ratio | 348 x | -58.6 x | 236 x | -395 x | -32.7 x | -4.97 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 6.04 x | 9.97 x | 42.1 x | 47.8 x | 6.8 x | 8.1 x |
| EV / Revenue | 6.72 x | 13.5 x | 53.1 x | 55.1 x | 8.82 x | 11.5 x |
| EV / EBITDA | 328 x | -101 x | -1,035 x | -665 x | 171 x | -109 x |
| EV / FCF | 109 x | -7.01 x | -16.5 x | 181 x | 28.4 x | 27.7 x |
| FCF Yield | 0.92% | -14.3% | -6.07% | 0.55% | 3.52% | 3.61% |
| Price to Book | 3.83 x | 2.95 x | 5.25 x | 10.1 x | 7.36 x | 13.8 x |
| Nbr of stocks (in thousands) | 684,884 | 684,884 | 684,884 | 684,884 | 684,884 | 684,884 |
| Reference price 2 | 4.870 | 3.870 | 7.330 | 13.43 | 6.760 | 3.380 |
| Announcement Date | 25/04/19 | 22/04/20 | 26/04/21 | 26/04/22 | 27/04/23 | 26/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 552.1 | 265.8 | 119.1 | 192.4 | 681.1 | 285.7 |
| EBITDA 1 | 11.31 | -35.52 | -6.118 | -15.93 | 35.11 | -30.18 |
| EBIT 1 | -2.82 | -50.75 | -20.52 | -41.65 | -87.37 | -167.7 |
| Operating Margin | -0.51% | -19.1% | -17.23% | -21.65% | -12.83% | -58.69% |
| Earnings before Tax (EBT) 1 | 11.95 | -55.87 | 20.07 | -28.51 | -165.8 | -516.4 |
| Net income 1 | 9.401 | -44.95 | 20.91 | -22.96 | -141.5 | -465.5 |
| Net margin | 1.7% | -16.91% | 17.55% | -11.94% | -20.77% | -162.94% |
| EPS 2 | 0.0140 | -0.0660 | 0.0310 | -0.0340 | -0.2070 | -0.6800 |
| Free Cash Flow 1 | 34.05 | -511.8 | -384.6 | 58.7 | 211.3 | 118.2 |
| FCF margin | 6.17% | -192.59% | -322.85% | 30.51% | 31.02% | 41.38% |
| FCF Conversion (EBITDA) | 301.05% | - | - | - | 601.7% | - |
| FCF Conversion (Net income) | 362.21% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 25/04/19 | 22/04/20 | 26/04/21 | 26/04/22 | 27/04/23 | 26/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 376 | 936 | 1,310 | 1,399 | 1,379 | 961 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 33.24 x | -26.35 x | -214.2 x | -87.78 x | 39.26 x | -31.83 x |
| Free Cash Flow 1 | 34.1 | -512 | -385 | 58.7 | 211 | 118 |
| ROE (net income / shareholders' equity) | 1.15% | -5.43% | 2.11% | -2.4% | -17.4% | -80.9% |
| ROA (Net income/ Total Assets) | -0.08% | -1.43% | -0.46% | -0.77% | -1.66% | -3.36% |
| Assets 1 | -11,960 | 3,138 | -4,550 | 3,000 | 8,530 | 13,852 |
| Book Value Per Share 2 | 1.270 | 1.310 | 1.400 | 1.330 | 0.9200 | 0.2400 |
| Cash Flow per Share 2 | 0.1100 | 0.2500 | 0.3000 | 0.1600 | 0.1300 | 0.0400 |
| Capex 1 | 73.5 | 499 | 733 | 251 | 59.3 | 57.7 |
| Capex / Sales | 13.31% | 187.87% | 615.29% | 130.23% | 8.71% | 20.19% |
| Announcement Date | 25/04/19 | 22/04/20 | 26/04/21 | 26/04/22 | 27/04/23 | 26/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -55.92% | 141M | |
| +5.97% | 105B | |
| -4.19% | 63.99B | |
| +51.90% | 42.95B | |
| +17.44% | 39.2B | |
| +6.62% | 33.01B | |
| +13.00% | 20.33B | |
| +15.64% | 17.29B | |
| +22.55% | 15.72B | |
| +7.34% | 14.72B |
- Stock Market
- Equities
- 600165 Stock
- Financials Ningxia Zhongke Biotechnology Co., Ltd
